Thursday 11th March 2021: 14:00 GMT

We describe the importance and benefits of an integrated approach to in vitro cardiac safety testing and the CiPA paradigm. We show how the combination of high-throughput and rapid automated ion channel testing, and more complex models of cardiac safety, inform decision making during drug discovery.

Chair

Ned Wakeman
Director of the  Alderley Park Accelerator

Speakers

Dr Michael Morton 
Co-Director and Co-Founder ApconiX Limited

A co-founder of ApconiX, Mike is an expert electrophysiologist and ion channel biologist with extensive experience gained in academia and industry. Mike’s career has spanned pure research, ion channel assay development and large-scale screening of all manner of ligand- and voltage-gated ion channels. Mike learned his craft as a postdoctoral fellow first at Leeds (with Malcolm Hunter) then at Yale (with Fred Sigworth) before joining the global ion channel initiative at AstraZeneca where his skills were applied to drug projects. Mike has a serious passion for ion channels and enjoys working with collaborators and clients alike to ensure the highest quality data are used to support better decision-making.

Richard Printemps
MSc CSO and Test Facility Management at PhysioStim

With more than 17 years of experience at PhysioStim, Richard is one of the most qualified Study Directors of in-vitro preclinical GLP studies on cardiovascular safety. He obtained a Master of Science in pharmacology and physiology at the University of Poitiers (France) in 2003 ended by an 8 months internship in cardiovascular research division of Pierre Fabre, and joined PhysioStim at the end of his University Course. Richard has also received expert training to direct non-clinical studies and R&D projects as well as multisite studies within the GLP framework.